Valuation: Caplin Point Laboratories Limited

Market Cap 191B 2B 1.74B 1.62B 1.49B 2.81B 2.85B 19.1B 7.5B 95.16B 7.52B 7.35B 319B P/E 2026
17.9x
P/E 2027 * 26.8x
Enterprise Value 191B 2B 1.74B 1.62B 1.49B 2.81B 2.85B 19.1B 7.5B 95.16B 7.52B 7.35B 319B EV / Sales 2026
5.23x
EV / Sales 2027 * 7.68x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.16%
1 day+1.87%
1 week-2.19%
Current month+1.87%
1 month+1.02%
3 months+47.66%
6 months+37.29%
Current year+39.49%
1 week 2,495.8
Extreme 2495.8
2,675
1 month 2,435.4
Extreme 2435.4
2,699
Current year 1,500.3
Extreme 1500.3
2,699
1 year 1,500.3
Extreme 1500.3
2,699
3 years 875.8
Extreme 875.8
2,699
5 years 575
Extreme 575
2,699
10 years 176.2
Extreme 176.2
2,699
Manager TitleAgeSince
Chief Executive Officer 71 27/03/2015
Director of Finance/CFO - 18/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 26/01/2010
Director/Board Member - 04/11/2025
Director/Board Member 71 27/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+1.94%-2.19% - - 2B
-2.29%-1.45%+18.48%+70.46% 50.03B
+3.60%+1.55%+56.17%+118.63% 36.6B
-0.86%+3.63%-3.60%+25.27% 12.47B
-1.00%+0.66%+16.34%+74.30% 11.77B
+2.70%-0.76%+30.73%+130.67% 9.04B
-1.95%-4.18%+41.45%-11.86% 7.03B
+0.08%+0.60%+13.89%+32.25% 6.79B
-0.85%+0.87%+6.75%+179.62% 6.6B
+0.39%+3.39%-35.25%+8.97% 5.49B
Average +0.17%+0.97%+16.11%+69.81% 16.2B
Weighted average by Cap. +0.04%+1.27%+24.97%+79.61%

Financials

2026 2027 *
Net sales 21.28B 223M 194M 180M 166M 313M 318M 2.13B 834M 10.59B 837M 819M 35.52B 24.88B 261M 227M 211M 194M 366M 371M 2.49B 976M 12.39B 979M 957M 41.53B
Net income 6.16B 64.55M 56.11M 52.23M 47.95M 90.56M 91.96M 616M 242M 3.07B 242M 237M 10.29B 7.13B 74.66M 64.91M 60.41M 55.47M 105M 106M 712M 279M 3.55B 280M 274M 11.9B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
03/08/26 2,565.60 +1.94% 53,685
31/07/26 ₹2,516.80 -0.77% 52,768
30/07/26 ₹2,536.30 -2.94% 82,641
29/07/26 ₹2,613.20 +0.96% 86,491
28/07/26 ₹2,588.30 -1.26% 106,528
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,514.70INR
Average target price
2,505.00INR
Spread / Average Target
-0.39%

Quarterly revenue - Rate of surprise